U.S., Feb. 27 -- ClinicalTrials.gov registry received information related to the study (NCT06846463) titled 'Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+' on Feb. 20.
Brief Summary: This study is a single-arm, open label, non-randomized, phase 2 trial of zanubrutinib in patients with diffuse large B-cell lymphoma (DLBCL) who have an MYD88 L265P mutation, a CD79B mutation, a NOTCH1 truncation, or who are CD5+ by immunohistochemistry (IHC).
Study Start Date: June 30, 2025
Study Type: INTERVENTIONAL
Condition:
Diffuse Large B-cell Lymphoma
DLBCL - Diffuse Large B Cell Lymphoma
Intervention:
DRUG: Zanubrutinib
Investigational Agent Administration. Zanubrutinib will be first administered on Cycle 2 Day 1 of ri...